Opioids are commonly used to treat pain in hospitalized patients; however, intravenous administration carries an increased risk of adverse effects compared with oral administration. The subcutaneous route is an effective method of opioid delivery with favorable pharmacokinetics.
O pioid medications are used widely for control of acute and chronic pain in hospitalized medical patients. While effective for analgesia, opioid administration via the intravenous route carries an increased risk of adverse effects, such as euphoria, nausea, and hypotension, compared with oral administration. 1 Furthermore, the intermittent, spiking pharmacokinetics of intravenous dosing are similar to the pattern known to drive the addiction process forward in animal models. 2 In the context of the current nationwide opioid crisis, significant efforts are under way to limit harm to patients by decreasing exposure to opioid medications; however, relatively little attention has been targeted to prescribing in the inpatient setting. The subcutaneous route of administration is an established, effective method of opioid delivery with welldescribed and more favorable pharmacokinetics than the intravenous route. Subcutaneous injection of morphine demonstrates equivalent bioavailability while achieving a slightly delayed rise to maximum plasma concentration compared with intravenous administration. 3 Previous studies have demonstrated efficacy of subcutaneous opioids in controlling pain in a range of patient populations, including postsurgical patients 4 recovering from cardiac surgery, 5 cesarean delivery, 6 major gynecologic surgeries, 7 and pediatric surgery, 8 as well as patients with pain related to cancer. 9, 10 A systematic review of 18 studies of various routes of opioid administration for control of cancer-related pain found no significant differences in efficacy or effectiveness compared with intravenous and subcutaneous routes. 1 We hypothesized that a 2-pronged approach of establishing a clinical practice standard and peer-to-peer education would reduce the use of intravenous opioids in favor of oral and subcutaneous opioid administration. The objective of the intervention was a reduction in exposure to intravenous opioids in a population of adult medical inpatients. By educating medical staff about subcutaneous administration, we hoped to see uptake of this wellproven method of drug delivery and both fewer intravenous opioid exposure events (ie, doses) and lower overall exposure to opioids (ie, morphine-milligram equivalents [MMEs] ). Pain scores were monitored to assess the effectiveness of analgesia.
Methods
This study was conducted on a 28-bed general adult medical inpatient unit in a large academic medical center. Prescribing medical staff included associates of a 165-member team of hospital-employed internal medicine attending physicians, nurse practitioners, and physician assistants. Six varying prescribers (3 physicians and 3 nurse practitioners and/or physician assistants) were caring for unit patients on each day of the control and intervention periods, and prescribers rotated through the unit in 3-to 7-day blocks according to a preestablished, unrelated scheduling system. Unit staff included 5 to 6 nurses per shift, with staff varying throughout the study period. A 3-month intervention period was established a priori and compared with a 6-month historical control period. This initiative met the Yale University Human Investigation Committee criteria to be considered a quality improvement project; need for patient consent was waived.
All patients present for at least 1 midnight on the intervention unit were included in the analysis, and only opioid doses dispensed on the intervention unit were included. Patient-days that included the administration of a parenteral opioid were separated as parenteral opioid patient-days for the purposes of subgroup analysis. Parenteral doses of morphine and hydromorphone, which are the preferred formulary agents for parenteral opioid therapy at the institution, and oral doses of morphine, hydromorphone, oxycodone, and tramadol were included in the analysis. For the purpose of analyzing MMEs, a conversion factor of 1 was used to compare subcutaneous and intravenous routes. 3 The electronic health record (Epic Hyperspace; Epic Systems Corp) was used as the primary data source; all prescribing information, dose administration information, and pain score entries were electronically captured as part of routine workflow. Pain scores were measured on a standard 0-to 10-point Likert scale (10 representing the worst pain), with nursing staff collecting patient-reported scores per routine hospital protocol.
Intervention
The intervention consisted of 2 elements: the adoption of a local opioid standard of practice for the unit and associated education for medical and nursing staff. The opioid standard of practice established the oral route of administration as preferred when patients were able to tolerate oral intake of any kind and established the subcutaneous route as preferred whenever parenteral opioids were required. Prescribing was not formally restricted; thus, the intravenous route remained available to prescribers throughout the intervention period. The standard of practice was developed and deployed jointly by physician (A.L.A.), physician assistant (S.M.M.), and nursing (D.L.D., C.L.H.) unit leadership.
Education was implemented for prescribers and nursing staff, targeting awareness of the subcutaneous route of opioid administration and the new local opioid standard of practice, as well as reviewing opioid equianalgesic conversion principles and basic pharmacokinetics. At the start of the 3-month
Key Points
Question Can adopting a new standard of inpatient opioid prescribing that prefers oral and subcutaneous over intravenous administration result in reduced intravenous opioid exposure?
Findings In this pilot study of 127 patients and 2459 patient-days on an adult medical unit, intravenous opioid dosing was reduced by 84% after adopting an opioid standard of practice, with mean pain scores similar to those before implementation of the new standard.
Meaning This intervention may be associated with significant reduction in inpatient intravenous opioid exposure in adult medical patients; further investigation is warranted.
intervention period, study investigators provided prescribers a 30-minute formal didactic presentation on these principles with the opportunity for questions and answers, as well as similar information via email. Follow-up email reminders were sent to prescribers at the 2-and 4-week marks. As part of a preexisting, twice-daily nursing "huddle," reminders and reinforcement were provided by nursing leadership to the unit nursing staff for 2 weeks prior to the formal introduction of the new standard of practice on the unit. Nurses were empowered to remind prescribers about the new standard.
Outcome Measures
The primary outcome was the number of intravenous opioid doses administered to the general inpatient population per patient-day. Secondary outcomes included total parenteral (intravenous and subcutaneous) doses administered per patient-day, the daily rate of patients on the unit administered any parenteral opioid, parenteral and overall opioid doses administered per patient-day, parenteral and overall opioid dosage administered in MMEs per patient-day, 11 and patients' mean reported pain score over each of the first 5 days of hospitalization.
Statistical Analysis
Statistical testing was performed using χ 2 analysis for categorical data; 2-tailed, unpaired t test for continuous data; and mixed-effects regression modeling to adjust for clustering of observations (Microsoft Excel, Microsoft Corp; RStudio). Findings were considered significant at P < .05.
Results
The 6-month control period and 3-month intervention period included 4500 patient-days and 2459 patient-days, respectively. Patients were similar between groups with respect to age, sex, body mass index, race, and primary discharge diagnosis category (Table) . During the intervention, 65% of parenteral opioid doses were administered via the subcutaneous route compared with less than 1% during the control period. Among the general patient population, intravenous opioid doses were reduced by 84% during the intervention period (0.06 vs 0.39 doses per patient-day, P < .001), and combined doses of parenteral opioids given by either intravenous or subcutaneous route were reduced by 55% (0.18 vs 0.39 doses per patient-day, P < .001) ( Figure 1A) . The daily rate of unit patients administered any parenteral opioid decreased by 57% during the intervention period (6% vs 14%, P < .001) period. In addition, the mean (SD) daily amount of parenteral opioids administered (measured in MMEs) decreased by 49% during the intervention period (2.88 [0.72] vs 5.67 [1. 14] MMEs per patient-day) ( Figure 1B) . Doses of opioids given via either the oral or parenteral route were reduced by 23% during the intervention (0.73 vs 0.95 doses per patient-day, P = .02) ( Figure 1C) , and mean daily overall MME exposure decreased by 31% (6.30 [4. 12] vs 9.11 [7. 34] MMEs per patient-day) ( Figure 1B) . Mean pain scores were assessed for each patient receiving opioid therapy for the first 5 days of hospitalization. For hospital days 1 through 3, there were no significant differences in mean reported postintervention vs preintervention pain score (day 1: 5.62 vs 5.81; difference, -0.19; 95% CI, -0.94 to 0.56; P = .62; day 2: 4.79 vs 5.27; difference, -0.49; 95% CI, -1.01 to 0.03; P = .07; and day 3: 4.24 vs 4.78; difference, −0.54; 95% CI, -1.18 to 0.09; P = .09); however, significant improvement was seen in the intervention group on day 4 (3.75 vs 4.82; difference, −1.07; 95% CI, −1.80 to −0.34; P = .004) and day 5 (3.59 vs 4.65; difference, −1.06; 95% CI, −1.84 to −0.27; P = .009) (Figure 2) .
Among the daily subset of patients receiving parenteral opioids, intravenous opioid doses were reduced by 62% during the intervention (1.03 vs 2.73 doses per parenteral-opioid patient-day, P < .001), while combined doses of parenteral opioids by either the intravenous or subcutaneous route did not differ significantly during the intervention (2.94 vs 2.82 doses per parenteral opioid patient-day, P = .31). 
Discussion
Reducing iatrogenic harm from exposure to opioids is currently a focus of efforts across multiple medical specialties. With a recent study showing increased persistent opioid use after exposure in the perioperative setting, 12 hospitalassociated opioid administration is an area deserving more attention. The literature does not currently include interventions specifically aiming to reduce the use of intravenous opioids by encouraging use of the equally efficacious and potentially less addicting subcutaneous route. We designed a 2-part quality improvement initiative targeted to prescribers and nursing staff caring for patients on a 28-bed general adult medical unit. First, a local opioid standard of practice was established, with oral administration preferred for patients tolerating oral intake. If patients were unable to take pills, subcutaneous administration was preferred, although prescribers were not restricted in ordering any drug or route as part of this investigation. With targeted education, prescribers received information about the subcutaneous route and were made aware of the new local standard of practice; nursing staff were encouraged to actively question orders noted to be outside of the preferred standard.
Prescriber uptake of the subcutaneous route for parenteral administration was brisk, with 65% of parenteral doses given via subcutaneous injection during the intervention compared with minimal subcutaneous use during the control period. The daily rate of patients receiving parenteral opioids of any kind decreased by half; to some degree, this result reflects the preference for oral administration in appropriate patients. Significant reductions were observed in intravenous, parenteral (intravenous and subcutaneous), and combined oral and parenteral opioid doses administered during the intervention period. Similarly, overall patient exposure to both oral and parenteral opioids was significantly reduced when measured as MMEs. These results show that the intervention was associated with reduction in overall actual opioid exposure and that patients were not administered the same amount of parenteral opioid via a different route. At the same time, mean pain scores were similar or improved in the intervention group compared with the control group over the first 5 days of hospitalization.
While we hoped to see pain scores remain similar in the intervention group, an unexpected improvement was observed; there may be several explanations for this phenomenon. First, switching from intravenous to subcutaneous administration for parenteral opioids may have decreased exposure to the intermittent, spiking levels of drug and thereby decreased short-term dependence on the parenteral opioid for pain control. Switching from parenteral opioid administration to oral administration may have provided more longacting, consistent pain control. Finally, an overall increase in awareness of opioid prescribing practices may have led to wider use of multimodal analgesic principles among prescribers and thereby less prescribing of opioids in general.
Limitations
To our knowledge, this is the first intervention of its kind in the literature. It was limited in that it was a pilot project conducted on a single adult inpatient medical unit in 1 academic medical center. Prescribers were all hospital-employed physicians and advanced practice clinicians, which likely helped to facilitate dissemination of education more quickly than in a setting in which several disparate groups of prescribers would be caring for patients. Prescribers in specialties other than internal medicine (ie, surgical specialties) were not involved in 
Research Original Investigation Opioid Standard of Practice Adoption and Intravenous Opioid Exposure in Hospitalized Patients
this study; whether it could be generalizable to other areas of practice has not yet been investigated. In addition, it is possible that any discomfort associated with subcutaneous opioid administration may not have been captured effectively by routine evaluation of pain scores. These results occurred without any changes made to the electronic health record (ie, electronic decision support for opioid prescribing or changing electronic order entry default buttons away from automatically selecting the intravenous route for parenteral opioids). Changes such as these could potentially increase the outcome of the intervention further by supporting the new standard of practice. This intervention should be scalable to larger populations of inpatients, and future directions may include study in other areas of hospital practice, including the surgical, emergency, obstetric, pediatric, and critical care environments. This expansion could be facilitated by leveraging both additional peer-to-peer education across medical specialties as well as the electronic health record, providing real-time decision support along with central pharmacy monitoring o f o p i o i d p r e s c r i b i ng . S e ve r a l q u e s t i o n s r e m a i n unanswered, such as whether adopting the new standard of practice can lead to decreased time from hospital admission to the transition from parenteral to oral opioids for acute pain and whether the intervention is associated with decreased length of stay, opioid-associated delirium, or the rate of patients discharged from the hospital with opioid prescriptions.
Conclusions
Adoption of a new standard of inpatient opioid prescribing, preferring the oral route of administration when available and the subcutaneous route when parenteral administration is required, coupled with education of prescribers and nursing staff, was associated with a reduction of inpatient exposure to intravenous opioids with improved pain control.
